![]() |
|
|
Vol. 297, Issue 3, 1166-1175, June 2001
Pharmacokinetics Research Laboratory, Tokushima Research Center,
Taiho Pharmaceutical Co., Ltd., Tokushima, Japan
5-Fluorouracil (5-FU) is a widely used antineoplastic agent. 5-FU
therapy often causes gastrointestinal toxicity, which is suppressed by
concomitant administration of potassium oxonate (Oxo). Here, we
investigated the effect of 5-FU on the small-intestinal drug-metabolizing enzymes, which play important roles in the first-pass metabolism of drugs, in rats, by enzyme measurements and immunoblot analyses. During repeated administration of a combination of
1-(2-tetrahydrofuryl)-5-fluorouracil, an oral 5-FU-derivative drug, and
5-chloro-2,4-dihydroxypyridine (FCD), an inhibitor of 5-FU degradation,
the activities of 7-ethoxyresorufin-O-deethylase, testosterone 6
-hydroxylase, 4-methylumbelliferone
UDP-glucuronyltransferase, and 1-chloro-2,4-dinitrobenzene glutathione
S-transferase decreased significantly on day 4, and the
activity of NADPH-cytochrome P450 (CYP) reductase decreased
significantly on day 7. These effects were found to be attributable to
a reduction in the enzyme protein contents in the small-intestinal
mucosa. The enzymatic alterations significantly increased the plasma
concentrations of orally administered nifedipine, which was prevented
by concomitant administration of Oxo with FCD. However, consecutive
administration of FCD for 4 days did not cause any alterations in the
activity of the hepatic CYP isozyme-supported testosterone hydroxylase.
These results suggest that continuous exposure to 5-FU leads to a
decrease in the activities of drug-metabolizing enzymes in the
intestinal mucosa by decreasing their enzyme protein contents, and
increases the plasma concentrations of orally administered nifedipine,
and that the sensitivity of these enzymes to the drug is greater than that of the enzymes of the liver. These effects were prevented by
concomitant administration of Oxo.
This article has been cited by other articles:
![]() |
Q.-Y. Zhang, L. S. Kaminsky, D. Dunbar, J. Zhang, and X. Ding Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine Drug Metab. Dispos., September 1, 2007; 35(9): 1617 - 1623. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Kaminsky and Q.-Y. Zhang THE SMALL INTESTINE AS A XENOBIOTIC-METABOLIZING ORGAN Drug Metab. Dispos., December 1, 2003; 31(12): 1520 - 1525. [Full Text] [PDF] |
||||
![]() |
N. Petri, C. Tannergren, B. Holst, F. A. Mellon, Y. Bao, G. W. Plumb, J. Bacon, K. A. O'Leary, P. A. Kroon, L. Knutson, et al. ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO Drug Metab. Dispos., June 1, 2003; 31(6): 805 - 813. [Abstract] [Full Text] [PDF] |
||||